Evaluation of efficacy of treatment of patients with diabetes mellitus type 2 with the use of different treatment schemes

Cover Page


Aim. To study pharmaco-epidemiological features of hypoglycemic treatment combinations in patients with diabetes mellitus type 2.

Methods. Cross-sectional epidemiologic study included 528 patients who responded the questions from ARIC questionnaire about the scheme of conducted antidiabetic treatment. Glycemia <7 mmol/l was estimated as normal, and glycated hemoglobin ≥7% - as decompensation.

Results. Mono- and combined treatment was received by 94.3% of patients. In treatment tactics there were no statistically significant gender differences. 3% of patients followed only diet therapy, 4.5% received metformin monotherapy, 23.7% took sulfonylureas. 50.8% of patients received insulin monotherapy, 49.2% received 2 insulin medications. In patients receiving metformin, sulfonylureas, insulin and combined therapy glycemia was higher, than in naive patients (7.7%, p <0.05; 8.8%, p <0.05; 17.7%, p <0.01 and 9.8%, p <0.01, respectively), and there were no statistically significant differences in glycohemoglobin levels. 75.3% were administered dual therapy, 22.4% - triple therapy, 2.7% - quaternary therapy. In 93.9% of cases with dual therapy and in 69.4% with triple therapy the tretment was rational. On different schemes of hypoglycaemic treatment adequate control of diabetes mellitus was not achieved in most patients.

Conclusion. Although 97.3% of patients with diabetes type 2 received treatment, in 81% of them decompensation was revealed; to correctly manage the disease doctors should follow international guidelines, widely use new generations of antidiabetics and rational combinations, and to improve adherence of patients to treatment, improvement of work of diabetic schools is recommended.

About the authors

S Kh Mekhdiev

Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev

Author for correspondence.
Email: smehdiyev@mail.ru
Baku, Azerbaijan

I I Mustafaev

Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev

Email: smehdiyev@mail.ru
Baku, Azerbaijan

M N Mamedov

National Research Center for Preventive Medicine

Email: smehdiyev@mail.ru
Moscow, Russia


  1. Confederat L., Constantin S., Lupascu F. et al. Hypoglycemia induced by antidiabetic sulfonylureas. Rev. Med. Chir. Soc. Med. Nat. Lasi. 2015; 119 (2): 579-584. PMID: 26204670.
  2. Pantalone K.M., Hobbs T.M., Wells B.J. et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res. Care. 2015; 3 (1): e000093. doi: 10.1136/bmjdrc-2015-000093.
  3. Sola D., Rossi L., Schianca G.P. et al. Sulfonylureas and their use in clinical practice. Arch. Med. Sci. 2015; 11 (4): 840-848. doi: 10.5114/aoms.2015.53304.
  4. Verges B. Treatment of type 2 diabetes in patients with history of cardiovascular disease. Rev. Prat. 2015; 65 (8): 1050-1053.
  5. Fisman E.Z., Tenenbaum A. Antidiabetic treatment with gliptins:focus on cardiovascular effects and outcomes. Cardiovasc. Diabetol. 2015; 14: 129. doi: 10.1186/s12933-015-0294-0.
  6. Januckova-Zdarska D., Honek P., Dusek L. et al. Analysis of the development of metformin and sulfonylurea prescriptions in the Czech Republik. Vnitr. Lek. 2015; 61 (11 Suppl. 3): 3S25-29. PMID: 26652962.
  7. Sharma M., Nazareth I., Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016; 6꞉ e010210. doi: 10.1136/bmjopen-2015-010210.
  8. Kaiser A., Vollenweider P., Waeber G., Marques-Vidal P. Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the Colaus study. Diabet. Med. 2012; 29 (2): 190-197. doi: 10.1111/j.1464-5491.2011.03422.x.
  9. Gu W., Ji L., Guo X., Li J. The impact of glycosylated hemoglobin target value in treatment guidelines on glycemic control of type 2 diabetic in Chinese cities. Zhondhua Nei Ke Za Zhi. 2015; 54 (3): 193-196. doi: 10.3760/cma.j.issn.0578-1426.2015.03.006.
  10. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012; 367 (4): 319-328. doi: 10.1056/NEJMoa1203858.
  11. Huri H.Z., Lim L.P., Lim S.K. Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. Drug Des. Devel. Ther. 2015; 9: 4355-4371. doi: 10.2147/DDDT.S85676.
  12. Zhang L., Ji L., Guo L. et al. Treatment pattern and glycemic control in older adults with type 2 diabetes mellitus receiving only oral antidiabetics drugs in China. Diabetes Techol. Ther. 2015; 17 (11): 816-824. doi: 10.1089/dia.2015.0094.
  13. Kalra S., Aamir A.H., Raza A. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J. Endocrinol. Metab. 2015; 19 (5): 577-596. doi: 10.4103/2230-8210.163171.
  14. Huri H.Z., Ling D.Y., Ahmad W.A. Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. Drug Des. Devel. Ther. 2015; 9: 4735-4749. doi: 10.2147/DDDT. S87294.
  15. International Hypoglycaemia Group (Amiel S.A., Aschner P., Childs B. et al.). Minimizing hypoglycemia in diabetes. Diabetes Care. 2015; 38 (8): 1583-1591. doi: 10.2337/dc15-0279.



Abstract - 437

PDF (Russian) - 431


Article Metrics

Metrics Loading ...



© 2017 Mekhdiev S.K., Mustafaev I.I., Mamedov M.N.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies